Robin R. Young to Provide 10-Year Forecast at 3rd Annual Stem Cell Summit
on Feb. 26
PHILADELPHIA, Feb. 1 /PRNewswire/ -- Stem cell product sales in the United States totaled $36 million in 2007, a 119 percent increase from the previous year, and are expected to reach $87 million, a 144 percent increase, in 2008, according to Robin R. Young, CFA, a medical industry analyst ranked as one of The Wall Street Journal's "Best on the Street" and among Institutional Investor's top-10.
The projections are based on Young's analysis of adult and human embryonic stem cell products currently sold or in development for the orthopedics, cardiovascular, anti-inflammatory, diabetes, nerve repair and dental markets.
"In recent months we've seen the largest stem cell product purchases in this fast-growing industry," Young said. "Physicians have already treated several thousands of patients in the United States with stem cell products. Moreover, the results of the clinical trials involving these types of products have been very impressive. This is a transformational year with the first-ever human embryonic stem cell products expected to enter the clinic."
Young will provide additional market data at the 3rd Annual Stem Cell Summit, which will take place Feb. 26 in New York City. The meeting is slated to be the largest gathering of stem cell company executives, scientists, investors and physicians. Attendees will learn about the investment opportunities in the stem cell marketplace, the groundbreaking stem cell products physicians are using today, and the growing market potential in terms of revenues. More information, including attendee registration details, is available at http://www.stemcellsummit.com.
Young has more than 25 years of experience as an analyst. He is the
president of RRY Publications and the organizer of the Stem Cell Summit.
|SOURCE RRY Publications|
Copyright©2008 PR Newswire.
All rights reserved